Resverlogix's BET Protein Inhibitor RVX-208 Meets Primary Endpoint in SUSTAIN Clinical Trial in Patients With High Risk Cardiovascular Disease
Munich And Calgary, Alberta (ots/PRNewswire) - -- Significant Increase in Functional HDL Persisted Throughout the 24-week Study Period -- -- Results from ASSURE Study Expected H1 2013, Using IVUS to Measure Regression of Atherosclerotic Plaque -- TSX Exchange Symbol: RVX Resverlogix Corp. today announced that the ...
mehr